Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Akero Therapeutics (AKRO – Research Report) on February 28 and set a price target of $63.00. The company’s shares ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on ‘Squawk Box’ to discuss the potential challenges and opportunities the pharmaceutical industry may face under the ...

In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best performing pharma stocks so far in 2025. On February 20, Jared Holz ...

In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best performing healthcare stocks so far in 2025. Despite the ongoing craze ...

In addition, pharmacy services, especially those focused ... Akero Therapeutics, Inc. (NASDAQ:AKRO) is a clinical-stage company that develops transformational treatments for patients with serious ...